Ectopic fat, insulin resistance and non-alcoholic fatty liver disease

Proceedings of the Nutrition Society

Volumn 72, Issue 4, 2013, Pages 412-419

  Byrne, Christopher D ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Cardio metabolic risk factors; Ectopic fat; Energy balance; Non alcoholic fatty liver disease; Type 2 diabetes: CVD

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; DISEASE COURSE; ENERGY EXPENDITURE; FATTY LIVER; HUMAN; INSULIN RESISTANCE; LIPID STORAGE; LIVER DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PHYSICAL ACTIVITY; CANCER RISK; CARDIOMETABOLIC RISK; END STAGE LIVER DISEASE; LIPOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; META ANALYSIS (TOPIC); NONHUMAN; OBESITY; PATHOGENESIS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; VISCERA;

ECTOPIC FAT; FAT; INSULIN; UNCLASSIFIED DRUG;

ADIPOSITY; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; FATTY LIVER; GREAT BRITAIN; HUMANS; INSULIN RESISTANCE; MOTOR ACTIVITY; PREVALENCE; RISK FACTORS;

EID: 84893091115     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S0029665113001249     Document Type: Conference Paper

References (46)

1. McKeigue PM, Shah B & Marmot MG (1991) Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet 337, 382-386.
2. Hu FB, Willett WC, Li T, et al. (2004) Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med 351, 2694-2703.
3. Katzmarzyk PT, Janssen I, Ross R, et al. (2006) The importance of waist circumference in the definition of metabolic syndrome: Prospective analyses of mortality in men. Diabetes Care 29, 404-409.
4. Alberti KG, Eckel RH, Grundy SM, et al. (2009) Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640-1645.
5. Bluher M (2012) Are there still healthy obese patients? Curr Opin Endocrinol Diabetes Obes 19, 341-346.
6. Fox CS, Massaro JM, Hoffmann U, et al. (2007) Abdominal visceral and subcutaneous adipose tissue compartments: Association with metabolic risk factors in the Framingham Heart Study. Circulation 116, 39-48.
7. Yusuf S, Hawken S, Ounpuu S, et al. (2005) Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: A case-control study. Lancet 366, 1640-1649.
8. Seidell JC (2010) Waist circumference and waist/hip ratio in relation to all-cause mortality, cancer and sleep apnea. Eur J Clin Nutr 64, 35-41.
9. Krakauer NY & Krakauer JC (2012) A new body shape index predicts mortality hazard independently of body mass index. PLoS ONE 7, e39504.
10. Byrne CD, Olufadi R, Bruce KD, et al. (2009) Metabolic disturbances in non-Alcoholic fatty liver disease. Clin Sci (Lond) 116, 539-564.
11. Byrne CD (2012) Dorothy Hodgkin Lecture 2012: Nonalcoholic fatty liver disease, insulin resistance and ectopic fat: A new problem in diabetes management. Diabet Med 29, 1098-1107.
12. Targher G, Day CP & Bonora E (2010) Risk of cardiovascular disease in patients with non-Alcoholic fatty liver disease. N Engl J Med 363, 1341-1350.
13. Sattar N, Scherbakova O, Ford I, et al. (2004) Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 53, 2855-2860.
14. Ghouri N, Preiss D & Sattar N (2010) Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: A narrative review and clinical perspective of prospective data. Hepatology 52, 1156-1161.
15. Bhatia LS, Curzen NP, Calder PC, et al. (2012) Non-Alcoholic fatty liver disease: A new and important cardiovascular risk factor? Eur Heart J 33, 1190-1200.
16. Jornayvaz FR & Shulman GI (2012) Diacylglycerol activation of protein kinase C epsilon and hepatic insulin resistance. Cell Metab 15, 574-584.
17. Samuel VT & Shulman GI (2012) Mechanisms for insulin resistance: Common threads and missing links. Cell 148, 52-71.
18. Watt MJ, Barnett AC, Bruce CR, et al. (2012) Regulation of plasma ceramide levels with fatty acid oversupply: Evidence that the liver detects and secretes de novo synthesised ceramide. Diabetologia 55, 2741-2746.
19. Yang G, Badeanlou L, Bielawski J, et al. (2009) Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am J Physiol Endocrinol Metab 297, E211-E224.
20. Kolesnick RN & Kronke M (1998) Regulation of ceramide production and apoptosis. Annu Rev Physiol 60, 643-665.
21. Lipina C & Hundal H (2011) Sphingolipids: Agents provocateurs in the pathogenesis of insulin resistance. Diabetologia 54, 1596-1607.
22. Coleman RA & Lee DP (2004) Enzymes of triacylglycerol synthesis and their regulation. Prog Lipid Res 43, 134-176.
23. Cantley JL, Yoshimura T, Camporez JP, et al. (2013) CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ERpreventing diacylglycerol- mediated hepatic insulin resistance. Proc Natl Acad Sci USA 110, 1869-1874.
24. Montagnani A & Gonnelli S (2013) Antidiabetic therapy effects on bone metabolism and fracture risk. Diabetes Obes Metab [Epublication ahead of print]. doi: 10.1111/dom.12077.
25. Loke YK, Kwok CS & Singh S (2011) Comparative cardiovascular effects of thiazolidinediones: Systematic review and meta-Analysis of observational studies. BMJ 342, d1309.
26. Bosetti C, Rosato V, Buniato D, et al. (2013) Cancer risk for patients using thiazolidinediones for type 2 diabetes: A metaanalysis. Oncologist 18, 148-156.
27. Li P, Fan W, Xu J, et al. (2011) Adipocyte NCoR knockout decreases PPARg phosphorylation and enhances PPARg activity and insulin sensitivity. Cell 147, 815-826.
28. Cornu M, Albert V & Hall MN (2013) mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev 23, 53-62.
29. Koketsu Y, Sakoda H, Fujishiro M, et al. (2008) Hepatic overexpression of a dominant negative form of raptor enhances Akt phosphorylation and restores insulin sensitivity in K/KAy mice. Am J Physiol Endocrinol Metab 294, E719-E725.
30. Laplante M & Sabatini DM (2012) mTOR signalling in growth control and disease. Cell 149, 274-293.
31. Zhang C, Wendel AA, Keogh MR, et al. (2012) Glycerolipid signals alter mTOR complex 2 (mTORC2) to diminish insulin signalling. Proc Natl Acad Sci USA 109, 1667-1672.
32. Hagiwara A, Cornu M, Cybulski N, et al. (2012) Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab 15, 725-738.
33. Ekstedt M, Franzen LE, Mathiesen UL, et al. (2006) Longterm follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44, 865-873.
34. Targher G, Bertolini L, Padovani R, et al. (2010) Prevalence of non-Alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 53, 713-718.
35. Blachier M, Leleu H, Peck-Radosavljevic M, et al. (2013) The burden of liver disease in Europe: A review of available epidemiological data. J Hepatol 58, 593-608.
36. Ahmed MH & Byrne CD (2011) Non-Alcoholic fatty liver disease. In The Metabolic Syndrome, 2nd ed., pp. 245-277 [CD Byrne and SH Wild, editors]. Chichester: Wiley- Blackwell.
37. Morris JN, Heady JA, Raffle PA, et al. (1953) Coronary heart-disease and physical activity of work. Lancet 265, 1111-1120.
38. Manini TM, Everhart JE, Patel KV, et al. (2006) Daily activity energy expenditure and mortality among older adults. JAMA, J Am Med Assoc 296, 171-179.
39. Harrison SA & Day CP (2007) Benefits of lifestyle modification in NAFLD. Gut 56, 1760-1769.
40. Rodriguez B, Torres DM & Harrison SA (2012) Physical activity: An essential component of lifestyle modification in NAFLD. Nat Rev Gastroenterol Hepatol 9, 726-731.
41. Targher G & Byrne CD (2013) Diagnosis and management of non-Alcoholic fatty liver disease and its hemostatic/ thrombotic and vascular complications. Semin Thromb Hemost 39, 214-228.
42. Lim EL, Hollingsworth KG, Aribisala BS, et al. (2011) Reversal of type 2 diabetes: Normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 54, 2506-2514.
43. Hallsworth K, Fattakhova G, Hollingsworth KG, et al. (2011) Resistance exercise reduces liver fat and its mediators in nonalcoholic fatty liver disease independent of weight loss. Gut 60, 1278-1283.
44. Kistler KD, Brunt EM, Clark JM, et al. (2011) Physical activity recommendations, exercise intensity, and histological severity of non-Alcoholic fatty liver disease. Am J Gastroenterol 106, 460-468.
45. Strasser B, Siebert U & Schobersberger W (2010) Resistance training in the treatment of the metabolic syndrome: A systematic review and meta-Analysis of the effect of resistance training on metabolic clustering in patients with abnormal glucose metabolism. Sports Med 40, 397-415.
46. Strasser B & Schobersberger W (2011) Evidence for resistance training as a treatment therapy in obesity. J Obes 2011:482564.